Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy

Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy

Abstract Backgrounds The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non–small cell lung cancer (LA‐NSCLC). However, little is known about the predictive factors of durvalumab efficacy in this pop...

Full description

Bibliographic Details
Main Authors: Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu, Kei Sonehara, Satoshi Wasamoto, Shigeru Koyama, Fumiaki Yoshiike, Mineyuki Hama, Kenichi Nishie, Daichi Kondo, Toshihiko Agatsuma, Akane Kato, Munetake Takata, Shintaro Kanda, Masayuki Hanaoka, Tomonobu Koizumi
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Thoracic Cancer
Subjects:
Albumin
chemoradiotherapy
C‐reactive protein
durvalumab
non–small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14484

Internet

https://doi.org/10.1111/1759-7714.14484

Similar Items